Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

We conducted a phase I pharmacokinetic dose escalation study of a recombinant humanized anti-p185(HER2) monoclonal antibody (MKC-454) in 18 patients with metastatic breast cancer refractory to chemotherapy. Three or six patients at each dose level received 1, 2, 4 and 8 mg kg(–1) of MKC-454 as 90-mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tokuda, Y, Watanabe, T, Omuro, Y, Ando, M, Katsumata, N, Okumura, A, Ohta, M, Fujii, H, Sasaki, Y, Niwa, T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362960/
https://www.ncbi.nlm.nih.gov/pubmed/10604742
http://dx.doi.org/10.1038/sj.bjc.6690343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362960/
https://www.ncbi.nlm.nih.gov/pubmed/10604742
http://dx.doi.org/10.1038/sj.bjc.6690343

Ejemplares similares